Active Biotech's partner Ipsen initiates a proof-of-concept study with tasquinimod in additional cancer indications
(Thomson Reuters ONE) -
Lund, Sweden, October 19, 2012 - Active Biotech (NASDAQ OMX NORDIC: ACTI) today
announces that its partner Ipsen (Euronext: IPN; ADR: IPSEY, read press release
here) will initiate a new phase II, proof-of-concept clinical trial with
tasquinimod in a so-called umbrella study evaluating the compound in four
different tumor types.
The study will evaluate the safety and efficacy of tasquinimod in advanced or
metastatic hepato-cellular, ovarian, renal cell and gastric carcinomas in
patients who have progressed after standard therapies.
About Active Biotech
Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with
focus on autoimmune/inflammatory diseases and cancer. Projects in or entering
pivotal phase are laquinimod, an orally administered small molecule with unique
immunomodulatory properties for the treatment of multiple sclerosis, tasquinimod
for prostate cancer as well as ANYARA for use in cancer targeted therapy,
primarily of renal cell cancer. In addition, laquinimod is in Phase II
development for Crohn's and Lupus. An additional project in clinical development
is the orally administered compound 57-57 for Systemic Sclerosis. Please visit
www.activebiotech.com for more information.
For further information:
Active Biotech
Tomas Leanderson, President & CEO
Tel: +46 46 19 20 95
tomas.leanderson(at)activebiotech.com
Active Biotech AB (Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 46 19 20 00
Fax: +46 46 19 11 00
Active Biotech is obligated to publish the information contained in this press
release in accordance with the Swedish Securities Market Act. This information
was provided to the media for publication 7:00 a.m. CET on October 19, 2012.
Active Biotech?s partner Ipsen initiates a proof-of-concept study :
http://hugin.info/1002/R/1650576/532304.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Active Biotech via Thomson Reuters ONE
[HUG#1650576]
Unternehmensinformation / Kurzprofil:
Datum: 19.10.2012 - 07:16 Uhr
Sprache: Deutsch
News-ID 194147
Anzahl Zeichen: 2694
contact information:
Town:
LUND
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 209 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Active Biotech's partner Ipsen initiates a proof-of-concept study with tasquinimod in additional cancer indications"
steht unter der journalistisch-redaktionellen Verantwortung von
Active Biotech (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
